✨ Free AI Report
Dermapharm Holding SE: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Dermapharm Holding SE
Company Research

Dermapharm Holding SE: Business Overview, Financials & Competitive Analysis

Dermapharm Holding SE scores 7/10 on the AskCyborg Cyborg Score (Strong). Specialized European branded generics player with vertical integration advantages and strategic M&A execution, trading at reasonable valuations in a consolidating market. The company's portfolio spans over 900 active pharmaceutical ingredients, health products, and medical devices. Strong market position in Europe with integrated value chain and strategic acquisitions. Market cap.

What is Dermapharm Holding SE's industry? Dermapharm Holding SE (dermapharm.de) operates in Specialty & Generic Drug Manufacturers. AskCyborg classifies Dermapharm Holding SE under Specialty & Generic Drug Manufacturers in its company registry.

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals and healthcare products, founded in 1991 and based in Grünwald near Munich. The company manufactures and sells off-patent branded pharmaceutical ...

7/ 10Strong

Cyborg Score thesis

Specialized European branded generics player with vertical integration advantages and strategic M&A execution, trading at...

Read the full analyst-debate transcript →
Industry Specialty & Generic Drug Manufacturers
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Dermapharm Holding SE Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Dermapharm Holding SE

AskCyborg analysts argue the bull and bear cases for Dermapharm Holding SE across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Dermapharm Holding SE OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Dermapharm Holding SE Overview

Pro stress-test →

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals and healthcare products, founded in 1991 and based in Grünwald near Munich. The company manufactures and sells off-patent branded pharmaceutical products across Germany, France, Spain, Austria, Switzerland and internationally, operating through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business, offering branded generics, OTC products, and herbal extracts.

Strategic Profile

Pro stress-test →

The company's integrated business model comprises in-house development, production and distribution of brand products by a trained pharmaceutical sales force. Dermapharm's distinctive approach combines robust in-house research and development with targeted acquisitions, such as their acquisition of the Dr. Loges-Schuten pharmaceutical company, broadening their reach into phyto-pharmaceuticals and other sectors.

Competitive Landscape

Pro stress-test →

Dermapharm operates in the competitive European branded generics and OTC pharmaceutical market. Main competitors include larger pharmaceutical companies with generic divisions and specialized regional players. The company is active primarily in Germany, Switzerland and Austria, positioning it as a regional specialist in Central Europe with growing international exposure.

Industry Context

Dermapharm Holding SE operates in Specialty & Generic Drug Manufacturers.

Key facts

Founded: 1991 · Headquarters: Grünwald, Germany · Employees: 3,610 · Market cap: €2.04B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Dermapharm Holding SE.

  • Holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients
  • Generates revenue primarily from dermatological products, allergy treatments, systemic corticosteroids, and vitamin supplements, addressing both niche and mass-market demands across Europe
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2020Acquisition of Allergopharma from Merck KGaA
  • 2022Acquisition of C³ Group for medical cannabis
  • +1 moreTrack every material event for Dermapharm Holding SE as it happens. Explore monitoring →
Get alerted when Dermapharm Holding SE has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Branded Generics & OTC PharmaceuticalsGeneric pharmaceutical manufacturer→Allergy & Dermatology ProductsSpecialty pharmaceutical company→European Branded GenericsGlobal generic pharmaceutical manufacturer→

Compare Dermapharm Holding SE with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Dermapharm Holding SE operates in Specialty & Generic Drug Manufacturers. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty & Generic Drug Manufacturers research →
NEW · MCP server

Ask your AI assistant about Dermapharm Holding SE

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Dermapharm Holding SE and its top competitor on Cyborg Score”
“What did Dermapharm Holding SE do this quarter?”
“Is Dermapharm Holding SE a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Dermapharm Holding SE do?+
Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals and healthcare products, founded in 1991 and based in Grünwald near Munich. The company manufactures and sells off-patent branded pharmaceutical ...
What is Dermapharm Holding SE's Cyborg Score?+
Dermapharm Holding SE has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Dermapharm Holding SE's main competitors?+
Named competitors include Branded Generics & OTC Pharmaceuticals, Allergy & Dermatology Products, European Branded Generics. The full competitive landscape is in the AskCyborg report.
How can I get the full Dermapharm Holding SE research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Dermapharm Holding SE research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Dermapharm Holding SE over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.